Nonalcoholic fatty liver disease: new treatments.

ABSTRACT:

Purpose of review

Nonalcoholic fatty liver disease is the most common cause of liver dysfunction in the western world because of its close association with obesity, insulin resistance and dyslipidaemia. Nonalcoholic steatohepatitis (NASH) is a particular health concern due to the increased morbidity and mortality associated with progressive disease. At present, without specific targeted pharmacological therapies, the mainstay of therapy remains weight loss through dietary modification and lifestyle change; thus, the purpose of this review is to summarize the recent evidence for current and emerging therapies in NASH.

Recent findings

Some existing medications, including pioglitazones and angiotensin receptor antagonists, may be repurposed to help treat this condition. Vitamin

SUBMITTER: Hardy T 

PROVIDER: S-EPMC4482455 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature